Pfizer to present study findings from its expanded breast cancer portfolio

August 29, 2015

???We are working to improve our understanding of the mechanisms and biology of breast cancer to facilitate better matching of patients to treatments, with the goal of increased benefits from selected therapies,??? added Dr. Koehler. ???Whether it is through studying the addition of new compounds into existing regimens, or pursuing novel treatment strategies, we strive to improve outcomes for breast cancer patients worldwide.???

In ongoing support of the breast cancer community, new data from the BRIDGE (Bridging Gaps, Expanding Outreach ?? Metastatic Breast Cancer Patient) survey, a wide-reaching assessment of the needs, experiences and attitudes of women living with metastatic breast cancer (Poster #3085; December 12) will be presented. The survey was expanded to include 392 additional participants from four additional countries - Brazil, Venezuela, Canada and Australia. The survey now spans 13 countries across five continents, with a total of 1,342 respondents.

Additional Pfizer Data Presentations

New analyses from the TEAM (Tamoxifen, Exemestane, Adjuvant, Multicenter) trial will also be presented at SABCS, comparing five years of exemestane as initial therapy to tamoxifen followed by exemestane for five years: The TEAM trial, a prospective, randomized, Phase 3 trial in postmenopausal women with hormone-sensitive early breast cancer (Oral #11; December 10). Safety and efficacy of neratinib in combination with vinorelbine in ErbB2+ metastatic breast cancer (Poster #5095; December 12) Safety of neratinib in combination with capecitabine in patients with solid tumors: a phase 1/2 study (Poster #5108; December 12)

SOURCE Pfizer Inc.